Hepatic Effects of Rosiglitazone in Rats with the Metabolic Syndrome
Hepatic Effects of Rosiglitazone in Rats with the Metabolic Syndrome
复制标题
DOI：
10.1111/j.1742-7843.2010.00553.x
复制
发表时间：
2010-08-01
影响因子：
3.1
通讯作者：
Grozovski, Maria
中科院分区：
文献类型：
--
作者：
Ackerman, Zvi;Oron-Herman, Mor;Grozovski, Maria
给予富含果糖饮食的大鼠出现了人类代谢综合征和非酒精性脂肪性肝病的许多特征。在这项研究中，我们描述了罗格列酮对富果糖饮食大鼠的肝脏作用。大鼠随机分为三组。其中一组饲喂标准鼠粮6周，另外两组饲喂富含果糖的鼠粮6周。在开始富果糖饮食4周后，其中一个富果糖饮食组也给予罗格列酮（10 mg/kg/天），再持续2周。给予富含果糖的饮食大鼠罗格列酮与以下参数降低相关：血压（-17%）、血浆甘油三酯（-62%）、肝总脂（-19%）、肝甘油三酯（-61%）、肝丙二醛（-88%）、谷胱甘肽还原酶活性（-84%）。观察到血浆脂联素水平（+329%）、肝脏磷脂（+46%）、肝脏α -生育酚浓度（+24%）和肝脏对氧磷酶活性（+68%）增加。罗格列酮使肝大泡性脂肪变性评分降低，但肝纤维化无变化。罗格列酮对代谢综合征大鼠的肝脏有利作用有限：它能改善肝脏脂质代谢，减少大泡性脂肪变性，改善一些肝脏氧化-抗氧化环境，但对肝纤维化没有影响。
Rats given fructose-enriched diet develop many characteristics of the human metabolic syndrome and non-alcoholic fatty liver disease. In this study, we characterized the hepatic effects of rosiglitazone in fructose-enriched diet rats. Rats were randomly divided into three groups. One group was maintained on standard rat chow diet for 6 weeks, whereas the other two groups were given fructose-enriched diet for 6 weeks. Four weeks after the initiation of fructose-enriched diet, one of the fructose-enriched diet groups was also given rosiglitazone (10 mg/kg/day) for an additional 2 weeks. Rosiglitazone administration to the fructose-enriched diet rats was associated with decreases in the following parameters: blood pressure (-17%), plasma triglycerides (-62%), hepatic total lipids (-19%), hepatic triglycerides (-61%), hepatic malondialdehyde (-88%), glutathione reductase activity (-84%). An increase in adiponectin plasma levels (+329%), hepatic phospholipids (+46%), hepatic alpha-tocopherol concentrations (+24%) and hepatic paraoxonase activity (+68%) was observed. Rosiglitazone caused a decrease in hepatic macrovesicular steatosis score but no change in hepatic fibrosis. Administration of rosiglitazone, to rats with the metabolic syndrome has limited hepatic favourable effects: it improves hepatic lipid metabolism, decreases macrovesicular steatosis and improves some of the hepatic oxidative-anti-oxidative milieu but has no effect on hepatic fibrosis.